Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 11, 2017
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct 11, 2017) - VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's ...
October 11, 2017
BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
ALAMEDA, Calif.--  (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today ...
October 10, 2017
Aradigm Regains Compliance with NASDAQ Listing Requirements
HAYWARD, Calif. -- (BUSINESS WIRE) -- Aradigm Corporation (ARDM) (“Aradigm" or the “Company”) today announced that it received notice from The NASDAQ Capital Market (“NASDAQ”) indicating ...
October 10, 2017
CytoSorbents to Present at the 2017 BIO Investor Forum
MONMOUTH JUNCTION, N.J., Oct. 10, 2017 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ...
October 10, 2017
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117
ROCKVILLE, Md., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
October 10, 2017
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
PASADENA, Calif. -- (BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for ...
October 9, 2017
CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting
NEWARK, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that a late-breaking presentation describing results from a pre-planned interim analysis ...
October 8, 2017
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health ...
October 8, 2017
Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals (PRTK) announced the results of three sub-analyses from the Phase 3 OASIS-1 study that show ...
October 8, 2017
Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- New microbiology data from Paratek Pharmaceuticals (PRTK) show that its well-tolerated, once-daily, oral and IV, broad-spectrum investigational ...
October 8, 2017
Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock
TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the ...
October 8, 2017
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
October 3, 2017
Zogenix Prices Public Offering of Common Stock
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...
October 3, 2017
Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Liestal, Switzerland, October 3, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it will present additional data from the positive Phase III DELOS trial in patients with ...
October 3, 2017
AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research
Lausanne, Switzerland, - October 3, 2017 -   AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
October 3, 2017
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
VANCOUVER, British Columbia, and MENLO PARK, Calif., Oct. 3, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development ...
October 3, 2017
BioTime to Present at the Cell and Gene Meeting on the Mesa
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, ...
October 3, 2017
AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)
REHOVOT, Israel and NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide ...
October 3, 2017
Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017
BOSTON, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
October 2, 2017
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
PARIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development ...
Page 98 of 127